The global renal denervation (RDN) devices market is standing at the threshold of a transformative decade. Currently valued at USD 1.3 billion in 2025, the industry is projected to reach USD 4.5 billion by 2035, expanding at a robust CAGR of 13.2%. This growth reflects a fundamental shift in treating resistant hypertension, moving from pharmacological dependency to...